Literature DB >> 9001243

Assessing the pathogenic potential of the V(D)J recombinase by interlocus immunoglobulin light-chain gene rearrangement.

S N Bailey1, N Rosenberg.   

Abstract

Chromosomal translocations involving antigen receptor genes and oncogenes have been observed in several forms of lymphoid malignancy. Observations of their lymphocyte-restricted occurrence and a molecular analysis of some translocation breakpoints have suggested that some of these rearrangements are generated by V(D)J recombinase activity. However, a direct correlation between this activity and the generation of such rearrangements has never been established. In addition, because these aberrant rearrangements are usually detected only after a tumor has been formed, the frequency with which the recombinase machinery generates translocations has never been assessed directly. To approach these issues, immunoglobulin light-chain gene rearrangements were induced in pre-B cells transformed by temperature-sensitive mutants of Abelson murine leukemia virus and PCR was used to identify interlocus recombinants. Vlambda Jkappa and Vkappa Jlambda rearrangements as well as signal joints resulting from the recombination of Vlambda and Jkappa coding elements were recovered and were found to be similar in structure to conventional intrachromosomal joints. Because these products were detected only when the cells were undergoing active intralocus rearrangement, they provide direct evidence that translocations can be generated by the V(D)J recombinase machinery. Dilution analyses revealed that interlocus rearrangements occur about 1,000 times less frequently than conventional intralocus rearrangements. Considering the large numbers of lymphocytes generated throughout life, aberrant rearrangements generated by the V(D)J recombinase may be relatively common.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9001243      PMCID: PMC231815          DOI: 10.1128/MCB.17.2.887

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  Lymphoid V(D)J recombination: nucleotide insertion at signal joints as well as coding joints.

Authors:  M R Lieber; J E Hesse; K Mizuuchi; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

2.  Activation of immunoglobulin kappa gene rearrangement correlates with induction of germline kappa gene transcription.

Authors:  M S Schlissel; D Baltimore
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

3.  Analysis of VH gene replacement events in a B cell lymphoma.

Authors:  R W Kleinfield; M G Weigert
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

4.  V(D)J recombination: a functional definition of the joining signals.

Authors:  J E Hesse; M R Lieber; K Mizuuchi; M Gellert
Journal:  Genes Dev       Date:  1989-07       Impact factor: 11.361

5.  The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism.

Authors:  B A Malynn; T K Blackwell; G M Fulop; G A Rathbun; A J Furley; P Ferrier; L B Heinke; R A Phillips; G D Yancopoulos; F W Alt
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

6.  Formation and resolution of double-strand break intermediates in V(D)J rearrangement.

Authors:  D A Ramsden; M Gellert
Journal:  Genes Dev       Date:  1995-10-01       Impact factor: 11.361

7.  Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1.

Authors:  Y Y Chen; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

8.  Consistent breakage between consensus recombinase heptamers of chromosome 9 DNA in a recurrent chromosomal translocation of human T cell leukemia.

Authors:  B Tycko; T C Reynolds; S D Smith; J Sklar
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

9.  The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15.

Authors:  T Boehm; R Baer; I Lavenir; A Forster; J J Waters; E Nacheva; T H Rabbitts
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

10.  A cluster of chromosome 11p13 translocations found via distinct D-D and D-D-J rearrangements of the human T cell receptor delta chain gene.

Authors:  T Boehm; L Buluwela; D Williams; L White; T H Rabbitts
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  6 in total

1.  Activation of V(D)J recombination induces the formation of interlocus joints and hybrid joints in scid pre-B-cell lines.

Authors:  S Lew; D Franco; Y Chang
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Irradiation promotes V(D)J joining and RAG-dependent neoplastic transformation in SCID T-cell precursors.

Authors:  C J Williams; I Grandal; D J Vesprini; U Wojtyra; J S Danska; C J Guidos
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

3.  Cryptic signals and the fidelity of V(D)J joining.

Authors:  S M Lewis; E Agard; S Suh; L Czyzyk
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

4.  Differential requirements for cis and trans V(D)J cleavage: effects of substrate length.

Authors:  L E Huye; D B Roth
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

5.  V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.

Authors:  Rodrig Marculescu; Trang Le; Paul Simon; Ulrich Jaeger; Bertrand Nadel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

6.  In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability.

Authors:  Katrina Vanura; Bertrand Montpellier; Trang Le; Salvatore Spicuglia; Jean-Marc Navarro; Olivier Cabaud; Sandrine Roulland; Elodie Vachez; Immo Prinz; Pierre Ferrier; Rodrig Marculescu; Ulrich Jäger; Bertrand Nadel
Journal:  PLoS Biol       Date:  2007-03       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.